1-4 of 4 results for subject:"Myriad Genetics"
Librarians' tools
- Search time
- 0.191 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:"Myriad Genetics"
- We searched for
- subject_t:"Myriad Genetics" OR subject_ses:44473
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health, what recent progress there has been regarding his Department's discussions with Myriad Inc on the patent for testing breast cancer genes relating to hereditary breast cancer. - There have been no recent discussions with Myriad. (Holding answer 12 May 2003).
To ask the Secretary of State for Health, what recent progress there has been regarding his Department's discussions with Myriad Inc on the patent for testing breast cancer genes relating to hereditary breast cancer. - There have been no recent discussions with Myriad. (Holding answer 12 May 2003).
To ask the Secretary of State for Health, what his policy is on objections made to the European patent office to the patents on breast cancer genes owned by Myriad Inc.
To ask the Secretary of State for Health, what his policy is on objections made to the European patent office to the patents on breast cancer genes owned by Myriad Inc.
To ask the Secretary of State for Health, what assessment he has made of the impact of the patents on breast cancer genes owned by Myriad Inc on testing for hereditary breast cancer; and what negotiations his Department is involved in with Myriad on this issue.
To ask the Secretary of State for Health, what assessment he has made of the impact of the patents on breast cancer genes owned by Myriad Inc on testing for hereditary breast cancer; and what negotiations his Department is involved in with Myriad on this issue.
That this House expresses its dismay that the US company Myriad Genetics has applied in the United Kingdom and other European countries for patents on the breast cancer susceptibility genes BRCA1 and BRCA2; is concerned that the potential for the enforcement of very broad claims on human genes such as these could negatively affect genetic testing and limit the progress of medical research; accepts that biotechnology companies should be able to recoup the costs of genetic research but believes that the government must be capable of intervening in the public interest to avoid patient suffering and safeguard biomedical research; and calls on the Government to clarify the United Kingdom position on patenting human genes and to ensure that the focus of genetic research is not transferred from the laboratory to the courtroom.
That this House expresses its dismay that the US company Myriad Genetics has applied in the United Kingdom and other European countries for patents on the breast cancer susceptibility genes BRCA1 and BRCA2; is concerned that the potential for the enforcement of very broad claims on human genes such as...